

WIHS ID#

[Empty box for WIHS ID#]

SECTION B. CURRENT ANTIRETROVIRAL USE

B1. PARTICIPANT'S CURRENT ANTIRETROVIRAL THERAPY:

INSTRUCTIONS: USING INFORMATION FROM THE ANTIRETROVIRAL DOSAGE FORM (DSG), CHECK OFF EACH MEDICATION THAT THE PARTICIPANT REPORTED TAKING WITHIN THE LAST THREE DAYS. INDICATE THE TOTAL NUMBER OF ARVS TAKEN FROM EACH CLASS IN THE GRAY BOXES.

Multi-Class Combination Drugs

262 ___ Atripla (Sustiva + Viread + Emtriva)

Total Multi-Class Drugs

Nucleoside/Nucleotide Reverse

Transcriptase Inhibitors (NRTIs)

- 227 ___ Combivir (AZT + 3TC)
- 239 ___ Emtriva (emtricitabine, FTC)
- 204 ___ Epivir (lamivudine, 3TC)
- 254 ___ Epzicom (Ziagen + Epivir)
- 092 ___ Retrovir (AZT, zidovudine, ZDV)
- 240 ___ Trizivir (abacavir + AZT + 3TC)
- 253 ___ Truvada (Viread + Emtriva)
- 147 ___ Videx & Videx EC (didanosine, ddi)
- 234 ___ Viread (tenofovir)
- 159 ___ Zerit (stavudine, d4T)
- 218 ___ Ziagen (abacavir, ABC)

Total NRTIs

Non-Nucleoside Reverse Transcriptase Inhibitors

(NNRTIs)

- 255 ___ Intelence (etravirine, TMC-125)
- 194 ___ Rescriptor (delavirdine)
- 220 ___ Sustiva (efavirenz)
- 191 ___ Viramune (nevirapine)

Total NNRTIs

Protease Inhibitors (PIs)

- 238 ___ Aptivus (tipranavir)
- 212 ___ Crixivan (indinavir)
- 210 ___ Invirase (saquinavir)
- 217 ___ Kaletra (lopinavir + ritonavir)
- 249 ___ Lexiva (fosamprenavir)
- 211 ___ Norvir (ritonavir)
- 256 ___ Prezista (TMC-114, darunavir)
- 243 ___ Reyataz (atazanavir)
- 216 ___ Viracept (nelfinavir)

Total PIs

Entry Inhibitors (including Fusion Inhibitors)

- 233 ___ Fuzeon (T-20, enfuvirtide)
- 265 ___ Selzentry (maraviroc)

Total Entry Inhibitors

Integrase Inhibitors

- 264 ___ Isentress (raltegravir, MK-0518)

Total Integrase Inhibitors

Cellular Inhibitors

- 207 ___ Droxia or Hydrea (hydroxyurea)

Total Cellular Inhibitors

B2. CURRENT ANTIRETROVIRAL REGIMEN:

HAART is defined as the reported use of three or more antiretroviral medications, one of which has to be a PI, an NNRTI, one of the NRTIs abacavir or tenofovir, an integrase inhibitor (e.g., raltegravir), or an entry inhibitor (e.g., Maraviroc or enfuvirtide).

- ON HAART 7
- ON ANY OTHER ARV REGIMEN 8
- NOT ON ANY ANTIRETROVIRAL THERAPY (ART) 9

WIHS ID#

SECTION E. VERIFICATION OF ELIGIBILITY

INSTRUCTIONS: DETERMINE PARTICIPANT'S FINAL ELIGIBILITY GROUP BASED ON RESPONSES TO THE FOLLOWING QUESTIONS:

B2: CURRENT ART REGIMEN STATUS

C1 and C2: COMPLETION OF SPECIMEN COLLECTION

D1: CURRENT HIV STATUS

D2: MOST RECENT HIV RNA LEVEL

D2a: DURATION OF HIV RNA UNDETECTABILITY

E1. FINAL ELIGIBILITY GROUP:

HIV-uninfected	1
HIV-infected, on HAART, HIV RNA >50,000.....	2
HIV-infected, not on ART, HIV RNA >50,000	8
HIV-infected, on HAART, undetectable HIV RNA.....	4
HIV-infected, not on ART, undetectable HIV RNA for at least one year, two consecutive WIHS visits (elite suppressor).....	9
Not eligible, specimens not collected	6
Not eligible, does not meet criteria for an eligibility group.....	7